How many institutions held XRTX - XORTX Therapeutics Inc. - Common Shares, no par value per share in Q2 2024?

5 institutional investors reported XRTX - XORTX Therapeutics Inc. - Common Shares, no par value per share for Q2 2024. Use the holders table for investor-level position and value details.

XORTX Therapeutics Inc. - Common Shares, no par value per share (XRTX)

Q: What does CUSIP 98420Q306 represent in this 13F holders report?

CUSIP 98420Q306 is the security identifier for XRTX - XORTX Therapeutics Inc. - Common Shares, no par value per share used to aggregate holder disclosures.

CUSIP: 98420Q306

Q2 2024 13F Holders as of 30 Jun 2024

Type / Class: Equity / Common Shares, no par value per share
Shares outstanding: 5,782,525
Total 13F shares: 15,243
Share change: -1,435
Total reported value: $29,237
Price per share: $1.90
Number of holders: 5
Value change: -$34,492
Number of buys: 2
Number of sells: 1

Quarterly Holders Quick Answers

What is CUSIP 98420Q306?
CUSIP 98420Q306 identifies XRTX - XORTX Therapeutics Inc. - Common Shares, no par value per share in SEC institutional holdings data.

Need full ownership history?
Open the full security ownership history page.

Next holder-history checks

These links keep the next click tied to holder verification, nearby quarters, or outside-13F ownership context.

Back to full security ownership history for the broader multi-quarter picture.
Latest 13F filings for newly reported positions across managers.
Latest Schedule 13D/13G reports for ownership changes outside the 13F cadence.
SEC investors directory for manager drilldown.

Explore More Reporting Periods

Jump to adjacent filing periods for faster comparison and easier crawl discovery.

Newer quarter: Q3 2024
Previous quarter: Q1 2024

Recent filing periods for CUSIP 98420Q306:

Q1 2026 Q4 2025 Q3 2025 Q2 2025 Q1 2025 Q4 2024 Q3 2024 Q2 2024

Top shareholders of XRTX - XORTX Therapeutics Inc. - Common Shares, no par value per share (13F + 13D/G + 3/4/5)

Grouped by holder across the latest SEC ownership disclosures. Ownership % is shown only when it is directly reported or safely comparable across share classes.

Methodology: rows are grouped by holder and ranked by the holder's primary source value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.

Holder	Source	Role / Reporting	Ownership %	Shares	Holdings Value	12M Net Δ	As of	Details
BANK OF MONTREAL /CAN/	13F	Company	0.26%	14,994	$59,801	—	31 Mar 2024	13F
OSAIC HOLDINGS, INC.	13F	Company	0.02%	1,153	$4,266	—	31 Mar 2024	13F
JPMORGAN CHASE & CO	13F	Company	0%	254	$1,211	—	31 Mar 2024	13F
Clearstead Advisors, LLC	13F	Company	0%	277	$696	—	31 Mar 2024	13F

Institutional Holders of XORTX Therapeutics Inc. - Common Shares, no par value per share (XRTX) as of Q2 2024

As of 30 Jun 2024, XORTX Therapeutics Inc. - Common Shares, no par value per share (XRTX) was held by 5 institutional shareholders that filed Form 13F with the SEC. Together, they reported ownership of 15,243 shares. The largest 5 holders included CITADEL ADVISORS LLC, Royal Bank of Canada, OSAIC HOLDINGS, INC., Clearstead Advisors, LLC, and JPMORGAN CHASE & CO. This page lists 5 institutional shareholders reporting positions in this security for the Q2 2024 filing period.

Investor	Option	Weight %	Change %	Value $	* Price	Shares	Share Change	Activity	Report Period

Compare Q2 2024 vs Q1 2024 Across Filers

Q1 2024 holders

Q2 2024 holders

Holder diff

Investor	Q1 2024 Shares	Q2 2024 Shares	Share Diff	Share Chg %	Q1 2024 Value $	Q2 2024 Value $	Value Diff $	Value Chg %

Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).

Quarterly Holders Trend

Quarterly Value Trend

Quarterly Shares Trend

* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.